Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:TGM6-GRIK1

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: TGM6-GRIK1
	FusionPDB ID: 90530
	FusionGDB2.0 ID: 90530
		Hgene	Tgene
	Gene symbol	TGM6	GRIK1
	Gene ID	343641	2897
	Gene name	transglutaminase 6	glutamate ionotropic receptor kainate type subunit 1
	Synonyms	SCA35\|TG6\|TGM3L\|TGY\|dJ734P14.3	EAA3\|EEA3\|GLR5\|GLUR5\|GluK1\|gluR-5
	Cytomap	20p13	21q21.3
	Type of gene	protein-coding	protein-coding
	Description	protein-glutamine gamma-glutamyltransferase 6TGase YTGase-6transglutaminase y	glutamate receptor ionotropic, kainate 1excitatory amino acid receptor 3glutamate receptor 5
	Modification date	20200313	20200320
	UniProtAcc	.	P39086 Main function of 5'-partner protein: FUNCTION: Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. May be involved in the transmission of light information from the retina to the hypothalamus.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000202625, ENST00000381423, ENST00000477505,	ENST00000472429, ENST00000309434, ENST00000327783, ENST00000389124, ENST00000389125, ENST00000399907, ENST00000399909, ENST00000399913, ENST00000399914, ENST00000535441,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	2 X 1 X 1=2	12 X 9 X 6=648
	# samples	1	12
	** MAII score	log2(1/2*10)=2.32192809488736	log2(12/648*10)=-2.43295940727611 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: TGM6 [Title/Abstract] AND GRIK1 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: TGM6 [Title/Abstract] AND GRIK1 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	TGM6(2398219)-GRIK1(30949501), # samples:2
Anticipated loss of major functional domain due to fusion event.	TGM6-GRIK1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. TGM6-GRIK1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. TGM6-GRIK1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. TGM6-GRIK1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr20:2398219/chr21:30949501)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across TGM6 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across GRIK1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000202625	TGM6	chr20	2398219	+	ENST00000327783	GRIK1	chr21	30949501	-	2974	1739	61	2676	871
ENST00000202625	TGM6	chr20	2398219	+	ENST00000389125	GRIK1	chr21	30949501	-	2887	1739	61	2589	842
ENST00000202625	TGM6	chr20	2398219	+	ENST00000399913	GRIK1	chr21	30949501	-	2887	1739	61	2589	842
ENST00000202625	TGM6	chr20	2398219	+	ENST00000399914	GRIK1	chr21	30949501	-	2974	1739	61	2676	871
ENST00000202625	TGM6	chr20	2398219	+	ENST00000535441	GRIK1	chr21	30949501	-	2590	1739	61	2589	843
ENST00000202625	TGM6	chr20	2398219	+	ENST00000389124	GRIK1	chr21	30949501	-	2507	1739	61	2442	793
ENST00000202625	TGM6	chr20	2398219	+	ENST00000399907	GRIK1	chr21	30949501	-	2887	1739	61	2583	840
ENST00000202625	TGM6	chr20	2398219	+	ENST00000399909	GRIK1	chr21	30949501	-	2887	1739	61	2583	840
ENST00000202625	TGM6	chr20	2398219	+	ENST00000309434	GRIK1	chr21	30949501	-	2584	1739	61	2583	841
ENST00000381423	TGM6	chr20	2398219	+	ENST00000327783	GRIK1	chr21	30949501	-	2974	1739	61	2676	871
ENST00000381423	TGM6	chr20	2398219	+	ENST00000389125	GRIK1	chr21	30949501	-	2887	1739	61	2589	842
ENST00000381423	TGM6	chr20	2398219	+	ENST00000399913	GRIK1	chr21	30949501	-	2887	1739	61	2589	842
ENST00000381423	TGM6	chr20	2398219	+	ENST00000399914	GRIK1	chr21	30949501	-	2974	1739	61	2676	871
ENST00000381423	TGM6	chr20	2398219	+	ENST00000535441	GRIK1	chr21	30949501	-	2590	1739	61	2589	843
ENST00000381423	TGM6	chr20	2398219	+	ENST00000389124	GRIK1	chr21	30949501	-	2507	1739	61	2442	793
ENST00000381423	TGM6	chr20	2398219	+	ENST00000399907	GRIK1	chr21	30949501	-	2887	1739	61	2583	840
ENST00000381423	TGM6	chr20	2398219	+	ENST00000399909	GRIK1	chr21	30949501	-	2887	1739	61	2583	840
ENST00000381423	TGM6	chr20	2398219	+	ENST00000309434	GRIK1	chr21	30949501	-	2584	1739	61	2583	841

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000202625	ENST00000327783	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.001866349	0.9981337
ENST00000202625	ENST00000389125	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.002352697	0.99764735
ENST00000202625	ENST00000399913	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.002352697	0.99764735
ENST00000202625	ENST00000399914	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.001866349	0.9981337
ENST00000202625	ENST00000535441	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.004791382	0.99520856
ENST00000202625	ENST00000389124	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.005781924	0.9942181
ENST00000202625	ENST00000399907	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.002644433	0.9973556
ENST00000202625	ENST00000399909	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.002644433	0.9973556
ENST00000202625	ENST00000309434	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.004055776	0.9959442
ENST00000381423	ENST00000327783	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.001866349	0.9981337
ENST00000381423	ENST00000389125	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.002352697	0.99764735
ENST00000381423	ENST00000399913	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.002352697	0.99764735
ENST00000381423	ENST00000399914	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.001866349	0.9981337
ENST00000381423	ENST00000535441	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.004791382	0.99520856
ENST00000381423	ENST00000389124	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.005781924	0.9942181
ENST00000381423	ENST00000399907	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.002644433	0.9973556
ENST00000381423	ENST00000399909	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.002644433	0.9973556
ENST00000381423	ENST00000309434	TGM6	chr20	2398219	+	GRIK1	chr21	30949501	-	0.004055776	0.9959442

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for TGM6-GRIK1

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
TGM6	chr20	2398219	GRIK1	chr21	30949501	1739	559	LHESHAVRLGPQEGSELMPKALSTRI

Top

Potential FusionNeoAntigen Information of TGM6-GRIK1 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

TGM6-GRIK1_2398219_30949501.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:01	GPQEGSELM	0.931	0.8613	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:08	GPQEGSELM	0.9262	0.8659	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:03	GPQEGSELM	0.8608	0.8612	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:04	GPQEGSELM	0.4923	0.9708	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:02	GPQEGSELM	0.4923	0.9708	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B81:01	GPQEGSELM	0.0647	0.7745	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B82:01	GPQEGSELM	0.0317	0.5912	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B45:01	QEGSELMPKA	0.9936	0.9498	11	21
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B50:02	QEGSELMPKA	0.9829	0.762	11	21
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:08	LGPQEGSELM	0.8696	0.8824	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:03	LGPQEGSELM	0.7335	0.9099	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:01	LGPQEGSELM	0.727	0.9172	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:04	LGPQEGSELM	0.4581	0.9738	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:02	LGPQEGSELM	0.4581	0.9738	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B27:04	VRLGPQEGSEL	1	0.6261	6	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B27:07	VRLGPQEGSEL	0.9999	0.6243	6	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B07:10	VRLGPQEGSEL	0.9752	0.614	6	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B07:12	GPQEGSEL	0.9914	0.5169	9	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B39:10	GPQEGSEL	0.4572	0.9342	9	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-C01:30	LGPQEGSEL	0.9831	0.9783	8	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-C01:17	LGPQEGSEL	0.9763	0.9726	8	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B07:12	GPQEGSELM	0.8997	0.5118	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B56:04	GPQEGSELM	0.6151	0.6967	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:12	GPQEGSELM	0.4923	0.9708	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B39:10	GPQEGSELM	0.2398	0.9309	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B42:01	GPQEGSELM	0.0372	0.775	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-C01:17	RLGPQEGSEL	0.9808	0.9768	7	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B56:04	LGPQEGSELM	0.5729	0.721	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:12	LGPQEGSELM	0.4581	0.9738	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B39:10	LGPQEGSELM	0.3864	0.9661	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B07:12	RLGPQEGSELM	0.9782	0.6304	7	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-C01:02	LGPQEGSEL	0.9752	0.9729	8	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-C01:03	LGPQEGSEL	0.9554	0.9669	8	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:77	GPQEGSELM	0.931	0.8613	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:23	GPQEGSELM	0.9282	0.8845	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:13	GPQEGSELM	0.814	0.8671	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:11	GPQEGSELM	0.7116	0.8877	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B56:02	GPQEGSELM	0.6151	0.6967	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:22	GPQEGSELM	0.5225	0.6634	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:09	GPQEGSELM	0.4923	0.9708	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B67:01	GPQEGSELM	0.2726	0.8965	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B55:04	GPQEGSELM	0.2278	0.6531	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B82:02	GPQEGSELM	0.0317	0.5912	9	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-C01:03	RLGPQEGSEL	0.9947	0.9789	7	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-C01:02	RLGPQEGSEL	0.9865	0.9779	7	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B15:73	RLGPQEGSEL	0.9835	0.9646	7	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B15:30	RLGPQEGSEL	0.9563	0.9521	7	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B51:05	LGPQEGSELM	0.7486	0.5313	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:77	LGPQEGSELM	0.727	0.9172	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B56:02	LGPQEGSELM	0.5729	0.721	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:22	LGPQEGSELM	0.5237	0.6888	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B35:09	LGPQEGSELM	0.4581	0.9738	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B67:01	LGPQEGSELM	0.368	0.9529	8	18
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B27:06	VRLGPQEGSEL	0.9999	0.6945	6	17
TGM6-GRIK1	chr20	2398219	chr21	30949501	1739	HLA-B67:01	RLGPQEGSELM	0.7366	0.9232	7	18

Top

Potential FusionNeoAntigen Information of TGM6-GRIK1 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of TGM6-GRIK1

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
10237	VRLGPQEGSELMPK	TGM6	GRIK1	chr20	2398219	chr21	30949501	1739

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of TGM6-GRIK1

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B52:01	3W39	10237	VRLGPQEGSELMPK	-4.50853	-4.50853
HLA-B44:05	3DX8	10237	VRLGPQEGSELMPK	-4.62231	-4.62231

Top

Vaccine Design for the FusionNeoAntigens of TGM6-GRIK1

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
TGM6-GRIK1	chr20	2398219	chr21	30949501	11	21	QEGSELMPKA	AAGAAGGATCAGAGCTGATGCCCAAAGCTC
TGM6-GRIK1	chr20	2398219	chr21	30949501	6	17	VRLGPQEGSEL	TGAGGCTGGGGCCGCAAGAAGGATCAGAGCTGA
TGM6-GRIK1	chr20	2398219	chr21	30949501	7	17	RLGPQEGSEL	GGCTGGGGCCGCAAGAAGGATCAGAGCTGA
TGM6-GRIK1	chr20	2398219	chr21	30949501	7	18	RLGPQEGSELM	GGCTGGGGCCGCAAGAAGGATCAGAGCTGATGC
TGM6-GRIK1	chr20	2398219	chr21	30949501	8	17	LGPQEGSEL	TGGGGCCGCAAGAAGGATCAGAGCTGA
TGM6-GRIK1	chr20	2398219	chr21	30949501	8	18	LGPQEGSELM	TGGGGCCGCAAGAAGGATCAGAGCTGATGC
TGM6-GRIK1	chr20	2398219	chr21	30949501	9	17	GPQEGSEL	GGCCGCAAGAAGGATCAGAGCTGA
TGM6-GRIK1	chr20	2398219	chr21	30949501	9	18	GPQEGSELM	GGCCGCAAGAAGGATCAGAGCTGATGC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of TGM6-GRIK1

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
Non-Cancer	TGM6-GRIK1	chr20	2398219	ENST00000202625	chr21	30949501	ENST00000309434	TCGA-IC-A6RF-11A

Top

Potential target of CAR-T therapy development for TGM6-GRIK1

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

GRIK1

chr20:2398219

chr21:30949501

ENST00000389125

654_674

906.0

Transmembrane

Helical

Tgene

GRIK1

chr20:2398219

chr21:30949501

ENST00000389125

835_855

906.0

Transmembrane

Helical

Tgene

GRIK1

chr20:2398219

chr21:30949501

ENST00000399907

654_674

919.0

Transmembrane

Helical

Tgene

GRIK1

chr20:2398219

chr21:30949501

ENST00000399907

835_855

919.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to TGM6-GRIK1

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to TGM6-GRIK1

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)